

Form 51-102F3
Material Change Report

Item 1 Name and Address of Company

Lobe Sciences Ltd. ("Lobe" or the "Company")
Suite 1400, 1199 West Hastings Street
Vancouver, BC V6E 3T5

Item 2 Date of Material Change

January 15, 2021

Item 3 News Release

The news release was disseminated on January 18, 2021 through Newsfile Corp. and filed on SEDAR.

Item 4 Summary of Material Change

The Company announced the appointment of Philip J. Young as Chief Executive Officer, Corporate Secretary and a director of the Company and the resignation of Thomas Baird from the position of Chief Executive Officer of the Company. The Company also announced the grant of a total of 7,400,000 stock options to directors, officers and consultants of the Company.

Item 5.1 Full Description of Material Change

Please see attached Schedule "A".

Item 5.2 Disclosure for Restructuring Transactions

Not applicable.

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7 Omitted Information

No information has been omitted.

Item 8 Executive Officer

For more information, please contact Jonathan Gilbert, Executive Chairman Tel: 949-505-5623

Item 9 Date of report:

January 21, 2021

Schedule “A”

LOBE SCIENCES ANNOUNCES MANAGEMENT CHANGES AND NEW DIRECTOR

Appointment of Philip Young as CEO and director adds a seasoned executive with a track record of new device and therapeutics development, FDA/regulatory approvals, capital markets, M&A and operational success.

January 18, 2021 Vancouver, British Columbia – Lobe Sciences Ltd (“**Lobe**” or the “**Company**”) (CSE: LOBE) (OTC Pink: GTSIF) is pleased to announce the appointment of Mr. Philip J. Young as Chief Executive Officer, Corporate Secretary and a director of the Company, effective January 15, 2021. Mr. Young replaces Thomas Baird, who resigned as CEO as of the same date.

Philip Young is an accomplished CEO and innovative professional with 25 years of expertise in senior executive management and board roles, with significant mergers and acquisitions and equity financing experience. He has a proven track record in the biotech, medtech and pharmaceutical industries with expertise in dealing with FDA/regulatory frameworks as well as new device and therapeutics development. From 2015 until 2019, Mr. Young was the Founder, Chairman, and CEO of Exactus Inc. (“**Exactus**”), an OTCQB listed company he successfully transitioned from a medical technology company to a farming focused hemp-derived CBD company.

Prior to Exactus, Mr. Young was the president, CEO, and Director of AmpliPhi Biosciences Corp. (now Armata Pharmaceuticals Inc. NASDAQ:ARMP), a global biopharmaceutical company. He was also previously the President, CEO and a director of Osteologix Inc., where he was responsible for directing and managing all facets of the global pharmaceutical development company. He is the former Chief Business Officer and Executive Vice President of Insmid Inc., where he directed all financing, corporate and commercial communications activities. Prior thereto, he was the Vice President and General Manager of Neurex Corp., where he was involved with the negotiations for its US\$700 million acquisition by Elan Corporation. Mr. Young holds a Bachelor’s of Science from James Madison University.

Jonathan Gilbert, Executive Chairman of Lobe, states, “We are very pleased to have Philip join our Lobe executive team. His addition is the latest in our strategy to strengthen our overall team, including recent additions to our industry renowned research and development partner, our board of directors and strategic advisors. Phil brings a wealth of experience in building companies, developing therapeutics and creating shareholder value, which is expected to support our current focus on advancing Lobe’s proprietary nasal device, furthering our pre-clinical study with the University of Miami and growing the Company through M&A. He has a demonstrated track record of senior leadership skills, capital markets acumen and FDA and regulatory experience. We will leverage these attributes as we progress with our nasal mist device engineering and overall therapeutics development initiatives involving psychedelic medicine. We are excited by his commitment to achieve the Company’s key strategic priorities.”

Philip Young states, “I look forward to working closely with Lobe’s board and executive team to grow the Company. I see great potential in the Company in this exciting and evolving industry where I can utilize both my therapeutics development/regulatory expertise and M&A experience to add value. We plan on continuing to build on Lobe’s progress made to date, in particular on the nasal device engineering and pre-clinical study with the University of Miami, as well as actively pursuing other M&A growth objectives.”

The Company also announces the grant of stock options to certain directors, officers and consultants to purchase an aggregate of 7,400,000 common shares, at a price of \$0.15 per share for three years from the date of grant in

accordance with and subject to the terms of Lobe's stock option plan. 2,000,000 of the stock options are subject to vesting provisions, with 12.5% of such options vesting on the date of grant and 12.5% every quarter thereafter.

About Lobe Sciences Ltd.

Lobe is a growth-oriented research, technology & services company that provides financial, management, IP and branding support to businesses. The Company operates a portfolio of companies focused on developing transformational medicines and applies refined strategies to help partner companies reach their full potential. Based in Vancouver, BC, Lobe Sciences creates value through acquisitions and development of assets, products and technologies by leveraging its scientific, engineering, branding and operational expertise supported by strong capital markets acumen.

For further information please contact:

Lobe Sciences Ltd.

Jonathan Gilbert, Executive Chairman

info@lobesciences.com

Tel: (949) 505-5623

***THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE
ACCURACY OR ADEQUACY OF THIS RELEASE.***

Disclaimer for Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, progression with nasal mist device engineering and overall therapeutics development initiatives involving psychedelic medicine, the pursuit of M&A initiatives, creating shareholder value and growth of the business, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are risks detailed from time to time in the filings made by the Company with securities regulations. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; and that the current Board and management may not be able to attain the Company’s corporate goals and objectives. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.